<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">0236217</journal-id>
<journal-id journal-id-type="pubmed-jr-id">6077</journal-id>
<journal-id journal-id-type="nlm-ta">Neuropharmacology</journal-id>
<journal-id journal-id-type="iso-abbrev">Neuropharmacology</journal-id>
<journal-title-group>
<journal-title>Neuropharmacology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0028-3908</issn>
<issn pub-type="epub">1873-7064</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28625718</article-id>
<article-id pub-id-type="pmc">5662005</article-id>
<article-id pub-id-type="doi">10.1016/j.neuropharm.2017.06.017</article-id>
<article-id pub-id-type="manuscript">NIHMS887591</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Synaptic functions of endocannabinoid signaling in health and disease</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Araque</surname>
<given-names>Alfonso</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="author-notes" rid="FN1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Castillo</surname>
<given-names>Pablo E</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="author-notes" rid="FN1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Manzoni</surname>
<given-names>Olivier J</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="author-notes" rid="FN1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tonini</surname>
<given-names>Raffaella</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
<xref ref-type="author-notes" rid="FN1">*</xref>
<xref ref-type="author-notes" rid="FN2">§</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>Department of Neuroscience, University of Minnesota, Minneapolis, MN 55455, USA</aff>
<aff id="A2">
<label>2</label>Dominick P. Purpura Department of Neuroscience, Albert Einstein College of Medicine, New York, NY 10461, USA</aff>
<aff id="A3">
<label>3</label>Institut National de la Santé et et de la Recherche Médicale U901 Marseille, France; Université de la Méditerranée UMR S901 Aix-Marseille Marseille, France; INMED Marseille, France</aff>
<aff id="A4">
<label>4</label>Neuroscience and Brain Technologies Department, Istituto Italiano di Tecnologia, Genova, Italy</aff>
<author-notes>
<corresp id="FN1"><label>*</label><bold>Corresponding authors:</bold> Alfonso Araque (<email>araque@umn.edu</email>); Pablo E Castillo (<email>pablo.castillo@einstein.yu.edu</email>); Olivier J Manzoni (<email>olivier.manzoni@inserm.fr</email>); Raffaella Tonini (<email>raffaella.tonini@iit.it</email>)</corresp>
<fn id="FN2">
<label>§</label>
<p><bold>Leading Contact:</bold> Raffaella Tonini (<email>raffaella.tonini@iit.it</email>)</p>
</fn>
<fn fn-type="COI-statement" id="FN4">
<p>
<bold>Competing financial interests</bold>
</p>
<p>The authors declare no competing financial interests.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>27</day>
<month>6</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>15</day>
<month>6</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="ppub">
<day>15</day>
<month>9</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>15</day>
<month>9</month>
<year>2018</year>
</pub-date>
<volume>124</volume>
<fpage>13</fpage>
<lpage>24</lpage>
<!--elocation-id from pubmed: 10.1016/j.neuropharm.2017.06.017-->
<abstract>
<p id="P1">Endocannabinoids (eCBs) are a family of lipid molecules that act as key regulators of synaptic transmission and plasticity. They are synthetized “on demand” following physiological and/or pathological stimuli. Once released from postsynaptic neurons, eCBs typically act as retrograde messengers to activate presynaptic type 1 cannabinoid receptors (CB<sub>1</sub>) and induce short- or long-term depression of neurotransmitter release. Besides this canonical mechanism of action, recent findings have revealed a number of less conventional mechanisms by which eCBs regulate neural activity and synaptic function, suggesting that eCB-mediated plasticity is mechanistically more diverse than anticipated. These mechanisms include non-retrograde signaling, signaling via astrocytes, participation in long-term potentiation, and the involvement of mitochondrial CB<sub>1</sub>. Focusing on paradigmatic brain areas, such as hippocampus, striatum, and neocortex, we review typical and novel signaling mechanisms, and discuss the functional implications in normal brain function and brain diseases. In summary, eCB signaling may lead to different forms of synaptic plasticity through activation of a plethora of mechanisms, which provide further complexity to the functional consequences of eCB signaling.</p>
</abstract>
<kwd-group>
<kwd>Endocannabinoids</kwd>
<kwd>synaptic plasticity</kwd>
<kwd>hippocampus</kwd>
<kwd>striatum</kwd>
<kwd>prefrontal cortex</kwd>
<kwd>astrocytes</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>